Gilteritinib Changes AML Landscape

Oncology (Williston Park). 2019 Aug 23;33(8):683729.
No abstract available

MeSH terms

  • Aniline Compounds / therapeutic use*
  • Clinical Trials, Phase III as Topic
  • Drug Approval
  • Drug Resistance, Neoplasm
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / pathology
  • Mutation
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / genetics
  • Neoplasm Recurrence, Local / pathology
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazines / therapeutic use*
  • Salvage Therapy
  • Survival Rate
  • Treatment Outcome
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • Aniline Compounds
  • Protein Kinase Inhibitors
  • Pyrazines
  • gilteritinib
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3